LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists - Pipeline Insights, 2017

  • ID: 4085570
  • Drug Pipelines
  • Region: Global
  • 141 pages
  • DelveInsight
1 of 4

FEATURED COMPANIES

  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Immutep S.A.
  • Immutep S.A.
  • Prima BioMed Ltd
  • Regeneron Pharmaceuticals
  • MORE
LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists - Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists - Pipeline Insights, 2015 Report covers the LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. The Report also provides LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists related therapeutic assessments by molecule type, route of administration, monotherapy and combination products. The Report also highlights the discontinued and inactive projects in pipeline for LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope:
- Our report provides a LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists Landscape across the globe
- The report provides drug profiles which includes product description, MOA, licensors & collaborators, technology, development partner and chemical information
- Coverage of the LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists and also provide company profiling
- Pipeline products coverage based on various stages of development from NDA filings to discovery.
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to Buy:
- Complete Pipeline intelligence and complete understanding over therapeutics development for LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Track your competitors and develop strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Understand the market and choose right partners for in-licensing and out licensing for your valuable assets
- Understand the factors behind failed/discontinued projects and move ahead without leaving any stone unturned
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Immutep S.A.
  • Immutep S.A.
  • Prima BioMed Ltd
  • Regeneron Pharmaceuticals
  • MORE
LAG-3, TIM-3 & OX40 Overview
Total Products Overview
Products Share by Clinical Stages
Products Share by Pre-clinical and Discovery Stages
LAG-3 Antagonists
Pipeline Therapeutics
Therapeutics under Development by Companies
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I and IND)
Comparative Analysis
Discovery and Pre-clinical stage Products
Comparative Analysis
Therapeutic Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
TIM-3 Antagonists
Pipeline Therapeutics
Therapeutics under Development by Companies
Early Stage Products (Phase I and IND)
Comparative Analysis
Discovery and Pre-clinical stage Products
Comparative Analysis
Therapeutic Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
OX40 Agonists
Pipeline Therapeutics
Therapeutics under Development by Companies
Early Stage Products (Phase I and IND)
Comparative Analysis
Discovery and Pre-clinical stage Products
Comparative Analysis
Therapeutic Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Additional Information
Discontinued Products
Companies Involved in Therapeutics Development
Methodology
Consulting Services
About Us
Contact Us
Disclaimer
List of Tables
Table 1: Total Products for LAG-3 Antagonists, TIM-3 Antagonists and OX-40 Agonists, 2017
Table 2: Share of Products for LAG-3 Antagonists, TIM-3 Antagonists and OX-40 Agonists in Clinical Stages, 2017
Table 3: Share of Products for LAG-3 Antagonists, TIM-3 Antagonists and OX-40 Agonists in Pre-clinical and Discovery, 2017
Table 4: Number of Products under Development for LAG-3 Antagonists, 2017
Table 5: Number of Products under Development by Companies, 2017
Table 6: Mid Stage Products (Phase II), 2017
Table 7: Early Stage Products (Phase I and IND), 2017
Table 8: Discovery and Pre-clinical Stage Products, 2017
Table 9: Assessment by Monotherapy Products for LAG-3 Antagonists, 2017
Table 10: Assessment by Combination Products for LAG-3 Antagonists, 2017
Table 11: Assessment by Route of Administration for LAG-3 Antagonists, 2017
Table 12: Assessment by Stage and Route of Administration for LAG-3 Antagonists, 2017
Table 13: Assessment by Molecule Type for LAG-3 Antagonists, 2017
Table 14: Assessment by Stage and Molecule Type for LAG-3 Antagonists, 2017
Table 15: Number of Products under Development for TIM-3 Antagonists, 2017
Table 16: Number of Products under Development by Companies, 2017
Table 17: Early Stage Products (Phase I and IND), 2017
Table 18: Discovery and Pre-clinical Stage Products, 2017
Table 19: Assessment by Monotherapy Products for TIM-3 Antagonists, 2017
Table 20: Assessment by Route of Administration for TIM-3 Antagonists, 2017
Table 21: Assessment by Stage and Route of Administration for LAG-3 Antagonists, 2017
Table 22: Assessment by Molecule Type for TIM-3 Antagonists, 2017
Table 23: Assessment by Stage and Molecule Type for TIM-3 Antagonists, 2017
Table 24: Number of Products under Development for OX40 Agonists, 2017
Table 25: Number of Products under Development by Companies, 2017
Table 26: Early Stage Products (Phase I and IND), 2017
Table 27: Discovery and Pre-clinical Stage Products, 2017
Table 28: Assessment by Monotherapy Products for OX40 Agonists, 2017
Table 29: Assessment by Route of Administration for OX40 Agonists, 2017
Table 30: Assessment by Stage and Route of Administration for OX40 Agonists, 2017
Table 31: Assessment by Molecule Type for OX40 Agonists, 2017
Table 32: Assessment by Stage and Molecule Type for OX40 Agonists, 2017
Table 33: Discontinued Products, 2017
Table 34: Companies Involved in Therapeutic Development, 2017

List of Figures
Figure 1: Total Products for LAG-3 Antagonists, TIM-3 Antagonists and OX-40 Agonists, 2017 (%)
Figure 2: Share of Products for LAG-3 Antagonists, TIM-3 Antagonists and OX-40 Agonists in Clinical Stages, 2017 (%)
Figure 3: Share of Products for LAG-3 Antagonists, TIM-3 Antagonists and OX-40 Agonists in Pre-clinical and Discovery, 2017 (%)
Figure 4: Number of Products under Development for LAG-3 Antagonists, 2017
Figure 5: Mid Stage Products (Phase II), 2017
Figure 6: Early Stage Products (Phase I and IND), 2017
Figure 7: Discovery and Pre-clinical Stage Products, 2017
Figure 8: Assessment by Monotherapy Products for LAG-3 Antagonists, 2017
Figure 9: Assessment by Combination Products for LAG-3 Antagonists, 2017
Figure 10: Assessment by Route of Administration for LAG-3 Antagonists, 2017
Figure 11: Assessment by Stage and Route of Administration for LAG-3 Antagonists, 2017
Figure 12: Assessment by Molecule Type for LAG-3 Antagonists, 2017
Figure 13: Assessment by Stage and Molecule Type for LAG-3 Antagonists, 2017
Figure 14: Number of Products under Development for TIM-3 Antagonists, 2017
Figure 15: Early Stage Products (Phase I and IND), 2017
Figure 16: Discovery and Pre-clinical Stage Products, 2017
Figure 17: Assessment by Monotherapy Products for TIM-3 Antagonists, 2017
Figure 18: Assessment by Combination Products for TIM-3 Antagonists, 2017
Figure 19: Assessment by Route of Administration for TIM-3 Antagonists, 2017
Figure 20: Assessment by Stage and Route of Administration for TIM-3 Antagonists, 2017
Figure 21: Assessment by Molecule Type for TIM-3 Antagonists, 2017
Figure 22: Assessment by Stage and Molecule Type for TIM-3 Antagonists, 2017
Figure 23: Number of Products under Development for OX-40 Agonists, 2017
Figure 24: Early Stage Products (Phase I and IND), 2017
Figure 25: Discovery and Pre-clinical Stage Products, 2017
Figure 26: Assessment by Monotherapy Products for OX40 Agonists, 2017
Figure 27: Assessment by Route of Administration for OX40 Agonists, 2017
Figure 28: Assessment by Stage and Route of Administration for OX40 Agonists, 2017
Figure 29: Assessment by Molecule Type for OX40 Agonists, 2017
Figure 30: Assessment by Stage and Molecule Type for OX40 Agonists, 2017
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Bristol-Myers Squibb
  • Immutep S.A.
  • Regeneron Pharmaceuticals
  • Sanofi
  • Prima BioMed Ltd
  • Ono Pharmaceutical Co. Ltd
  • Immutep S.A.
  • GlaxoSmithKline
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll